These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 26802900)

  • 1. Current status of data on cangrelor.
    Qamar A; Bhatt DL
    Pharmacol Ther; 2016 Mar; 159():102-9. PubMed ID: 26802900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
    Waite LH; Phan YL; Spinler SA
    Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the Use of Cangrelor in the Real World.
    Qamar A; Bhatt DL
    Am J Cardiovasc Drugs; 2017 Feb; 17(1):5-16. PubMed ID: 27677505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor.
    Marcano AL; Ferreiro JL
    Curr Atheroscler Rep; 2016 Nov; 18(11):66. PubMed ID: 27714642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.
    Droppa M; Borst O; Rath D; Müller K; Gawaz M; Bhatt DL; Geisler T
    Cell Physiol Biochem; 2017; 42(4):1336-1341. PubMed ID: 28700987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cangrelor for treatment during percutaneous coronary intervention.
    Oestreich JH; Dobesh PP
    Future Cardiol; 2014 Mar; 10(2):201-13. PubMed ID: 24762247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
    Franchi F; Rollini F; Park Y; Angiolillo DJ
    Expert Opin Drug Saf; 2016; 15(2):275-85. PubMed ID: 26680584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility and safety of cangrelor in patients with suboptimal P2Y
    Selvarajah A; Tavenier AH; Bor WL; Houben V; Rasoul S; Kaplan E; Teeuwen K; Hofma SH; Lipsic E; Amoroso G; van Leeuwen MAH; Berg JMT; van 't Hof AWJ; Hermanides RS
    BMC Cardiovasc Disord; 2021 Jun; 21(1):292. PubMed ID: 34118880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cangrelor for treatment of arterial thrombosis.
    Walsh JA; Price MJ
    Expert Opin Pharmacother; 2014 Mar; 15(4):565-72. PubMed ID: 24479981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cangrelor: A Review in Percutaneous Coronary Intervention.
    Keating GM
    Drugs; 2015 Aug; 75(12):1425-34. PubMed ID: 26201463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cangrelor: a review on pharmacology and clinical trial development.
    Franchi F; Rollini F; Muñiz-Lozano A; Cho JR; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2013 Oct; 11(10):1279-91. PubMed ID: 24138516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-Analysis of the Role of Cangrelor for Patients Undergoing Percutaneous Coronary Intervention.
    Majmundar M; Kansara T; Jain A; Shah P; Mithawala P; Desai R; Shah P; Doshi R
    Am J Cardiol; 2019 Apr; 123(7):1069-1075. PubMed ID: 30654930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cangrelor: A New Route for P2Y12 Inhibition.
    Sible AM; Nawarskas JJ
    Cardiol Rev; 2017; 25(3):133-139. PubMed ID: 28379902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cangrelor for the treatment of patients with Arterial Thrombosis.
    Tantry U; Chaudhary R; Kubica J; Bliden K; Gurbel PA
    Expert Opin Pharmacother; 2018 Aug; 19(12):1389-1398. PubMed ID: 30102083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cangrelor for the management and prevention of arterial thrombosis.
    Storey RF; Sinha A
    Expert Rev Cardiovasc Ther; 2016 Sep; 14(9):991-9. PubMed ID: 27362653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
    Alexopoulos D; Pappas C; Sfantou D; Lekakis J
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):13-22. PubMed ID: 29228817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Periprocedural platelet inhibition with cangrelor in P2Y
    Droppa M; Spahn P; Takhgiriev K; Müller KAL; Alboji A; Straub A; Rath D; Jeong YH; Gawaz M; Geisler T
    Int J Cardiol; 2016 Nov; 223():848-851. PubMed ID: 27580219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Myocardial infarction: Role of new antiplatelet agents].
    Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP
    Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.